This forum is for questions about medical issues and research aspects of
Hepatitis C such as, questions about being newly diagnosed, questions about current treatments, information and participation in discussions about research studies and clinical trials related to Hepatitis. If you would like to communicate with other people who have been touched by Hepatitis, please visit our new
Hepatitis Social/Living with Hepatitis forum
Also I think HIV passes the brain/blood barrier, which HCV in most cases does not.
http://www.sumanasinc.com/webcontent/animations/content/lifecyclehiv.html
Life Cycle of Hepatitis C:
http://hopkins-gi.org/multimedia/database/intro_293_VC-04.swf
From Wikipedia, the free encyclopedia
A retrovirus is any virus belonging to the viral family Retroviridae. They are enveloped viruses possessing an RNA genome, and replicate via a DNA intermediate. Retroviruses rely on the enzyme reverse transcriptase to perform the reverse transcription of its genome from RNA into DNA, which can then be integrated into the host's genome with an integrase enzyme. The virus then replicates as part of the cell's DNA."
http://query.nytimes.com/gst/fullpage.html?res=9A00E6DF173EF932A25750C0A9659C8B63&sec=health&spon=&pagewanted=all
Think I found the answer. Better keep it to myself then.
"Hepatitis B is one of a few known non-retroviral viruses which use reverse transcription as a part of its replication process."
Source: Wikipedia
http://en.wikipedia.org/wiki/Hepatitis_B
I assume there is something in the HCV life cycle that makes it vulnerable while the other two can find a mechanism that allows it to escape the drugs. HIV is significantly impacted by PIs but somehow finds a way to protect enough virions to keep going and survive long enough to mutate. Anyway, luckily for us this is an academic issue in our case.
The way I understand viruses is that there is no cure by directly attacking the virus. Our immune system has to do the job. We can make the environment, ie our body, an unpleasant place for the virus, thereby helping the immune system in its effort to kill off the virus, and hopefully the virus will expire. Unfortunately, interferon and ribavirin do not only make the environment unpleasant for the hep C virus, but for us as well. Luckily, we are hardier than the hep C virus.
Also when the virus as with HIV and hep B has become a part of the DNA in the infected cells, I figure each infected cell must die for us to get rid of the disease. Apparently though, a small minority of chronic hep B patients are cured by interferon therapy.
Maybe the fact that HCV does not integrate into the cell DNA is the explanation why interferon works. Because of this HCV might be easier for the interferon enhanced immune system to kill.
Just my 2 cents.
I assume there is something in the HCV life cycle that makes it vulnerable"
_________________________
Interferon works in phases. Most of the virus is circulating in your bloodstream. The virus in your blood is the easiest to kill, because it doesn't live as long as the virus that is in liver cells. Also, it is out in the open, so to speak, and not hiding in cells.
The first phase of treatment lasts 1 to 2 days. This phase kills most of the virus circulating in your bloodstream. The action of Interferon in your bloodstream is simple. It mainly slows down the replication of the virus. In order for any life form to survive, it must live long enough to reproduce. By slowing down the rate of replication, the virus dies on its own without producing offspring.
Phase 2 lasts from day 2 through day 14. Interferon is now attacking the virus in your liver cells. This is a slow phase because the virus has trained the liver cells to look as though they aren't infected. The more your viral load drops, the more the interferon is able to see the the infected cells. The Hep C virus has turned the liver cells into virus reproduction factories. It teaches the liver cells how to make more copies of the virus. So now the action of interferon becomes more complicated. Interferon calls for help from other parts of your immune system. These other parts of your immune system degrade the RNA of the virus, interfere with the virus-making process and try to re-teach the liver cells how to behave normally.
Phase 3 lasts from day 14 through day 28, (and continues on through week 24). During this phase, interferon completely switches your immune system into full attack mode. Your immune system can now see which infected liver cells cannot be saved and starts to kill them. Interferon also encourages regeneration of liver cells, so as the infected cells are killed, new cells begin to grow in their place (this is how interferon may help reverse liver damage).
All of this activity takes place within 30 days. That's why your doctor expects to see a 2 log drop in your viral load within 12 weeks of treatment. It means that the interferon is sucessfully working on the virus that is actually in your liver (same with a 4 week RVR).
"I still don't see how the protease inhibitors and SOC can eliminate HCV but not HIV or HBV"
____________________________
The protease of HCV, NS3, is responsible for blocking interferon. That's why protease inhibitors like Telepravir and Boceprevir, are being used for Hep C treatment. They block replication and help interferon.
Co
---------------------------------
I suppose you can say that. But the PI's kill the wild type virus (which is the much larger number). You still need the interferon to kill the mutant type virus. And if somebody is interferon resistant, it's not going to work even if the PI lowered the viral load.
Co
Is this true? I thought an HCV copy was extremely short lived anyway. But that blood cells regenerate in 4 weeks, whereas liver cells regenerate in 300-500 days.
Do you have a link to what you stated in your post? It would be interesting to read the original link.
-------------------------------------------------------------------
http://www.hivandhepatitis.com/2008icr/aasld/docs/111108_a.html
Prove 3 results reported at AASLD 2008 (from 453 genotype 1 ----past TX failures)
"Based on these findings, the investigators stated, "In a population of patients who have failed previous [pegylated interferon/ribavirin] treatment, response rates 12 weeks after end of treatment were 52% overall in the T12/PR 24 arm: 73% in prior relapsers, 41% in prior non-responders."
(These were SVR 12 results and therefore not "official"-- Willy)
----------------------------------
Nowhere in my posts did I say, "non-responders". I said "interferon resistant".
"It appears that non-responders do indeed respond to Telaprevir triple therapy"
-----------------------------------
But were they null responders, or were they "non-responders" because they were under-dosed, their dose was reduced or interrupted, etc?
Co
--------------------------------------
HCV RNA negative strand, which shows replication, was found in the brain tissue of 3 out of 12 Hep C patients in this study.
According to the prevailing hypothesis, circulating lymphocytes cross the blood-brain barrier carrying HCV to the central nervous system ...and the virus is then replicated in the macrophages and microglia in the brain as a separate compartment.
HEPATITIS C VIRUS NEUROINVASION: IDENTIFICATION OF INFECTED CELLS.
Wilkinson J, Radkowski M, Laskus T.
St. Joseph's Hospital and Medical Center, Phoenix, Arizona; Institute of Infectious Diseases, Warsaw Medical University, Warsaw, Poland.
Hepatitis C virus (HCV) infection is often associated with cognitive dysfunction and depression. HCV sequences and replicative forms were detected in autopsy brain tissue and cerebrospinal fluid from infected patients suggesting direct neuroinvasion. However, the phenotype of cells harboring HCV in brain remains unclear. We studied autopsy brain tissue from 12 HCV-infected patients, 6 of these patients were coinfected with HIV. Cryostat sections of frontal cortex and subcortical white matter were stained with monoclonal antibodies specific for microglia/macrophages (CD68), oligodendrocytes (CNPase), astrocytes (GFAP) and neurons (NeuN), separated by laser capture microscopy (LCM) and tested for the presence of positive and negative strand HCV RNA. Sections were also stained with antibodies to viral nonstructural protein 3 (NS3), separated by LCM and phenotyped by real-time PCR. Finally, sections were also double stained with antibodies specific for cell phenotype and HCV NS3. HCV RNA was detected in CD68-positive cells in 8 patients and negative strand HCV RNA, which is a viral replicative form, was found in 3 of these patients. HCV RNA was also found in astrocytes from 3 patients, but negative strand RNA was not detected in these cells. In double immunostaining, 83%-95% of cells positive for HCV NS3 were also CD68-positive, while 4% to 29% were GFAP-positive. NS3-positive cells were negative for neuron and oligodendrocyte phenotypic markers. In conclusion, HCV infects brain microglia/macrophages and to a lesser extent astrocytes. Our findings could explain the biological basis of neurocognitive abnormalities in HCV infection.
http://www.ncbi.nlm.nih.gov/pubmed/19019968?ordinalpos=8&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel
Co
P.S. Things that cause deterioration of the blood-brain barrier and might make it easier for HCV to cross it......high blood pressure, microwaves and HIV. But I can't remember where I read that.
i asked my hepa about relapsed for HCV after tx, and she told me that relapse happens when people are reinfected. didn't mention anything about virus return from hiding in the body.
"But were they null responders, or were they "non-responders" because they were under-dosed, their dose was reduced or interrupted, etc?"
------------------------------------------------------
We will soon see, or at least better see. In the past it was virtually impossible to know exactly how and why people failed. Unless one had meticulous records of weekly viral loads, dosing records, etc it was a matter of supposition.
When the people who failed Prove 1 and Prove 2 (the SOC control arm "failures"; all geno 1 naives) were given the opportunity to be placed into rollover arms in which they were given triple therapy. We will be able to see all the classic groups of treatment failures (from null responder to relapsers) respond when given triple therapy. When they classify a person a null responder they will have fairly detailed records to prove it. It will then be followed up with detailed response rates to triple therapy given to the exact same people who had prior failed SOC.
Given the response rates of Prove 3 with past treatment failures I am hopeful that we will see null responders be converted into responders and perhaps even SVR success stories.
I am not trying to argue the point about interferon resistance but I would like to open up the possibility that even so called "null or non response" to SOC does not mean that one may not be able to be cured using protease or polymerase inhibitors (in conjunction with IFN & RBV) I think sometimes people attribute null response to interferon resistance. (I understand that presumably all interferon resistant people will be null responders (to current SOC) but that not all null responders are therefore interferon resistant. Does that sound right to you?)
I see that Rocker posted an article in which (it was claimed) that a Sherring-Plough 2nd generation PI in development was said to be 10X more powerful (in vitro) than existing PI's.(meaning Telaprevir and Boceprevir, presumably)
At some point the inhibitors may become effective enough that interferon (or RBV) will be dropped from treatment. That day may be here sooner than we think. Trials for such treatments may soon start several pharma's. Vertex had one planned on in 2009 I believe
By the way..... Vertex (well, actually Tibotech) will have a European trial which will utilize the SOC "lead in" before dosing Telaprevir on past treatment failures, null responders included. Figure over 18 months to get the trial started, dosed for a year and a 6 month wait for an "official" SVR PCR.
http://www.hivandhepatitis.com/hep_c/news/2008/102408_b.html
best,
Willy
Sorry for posting on youir thread..
I AM NOT A HIGH JACKER
---------------------------------------------------------------
Acturally, there are cures for several different kinds of cancer!
"I see that Rocker posted an article in which (it was claimed) that a Sherring-Plough 2nd generation PI in development was said to be 10X more powerful (in vitro) than existing PI's.(meaning Telaprevir and Boceprevir, presumably) "
---------------------------
By adding ritonavir, an HIV anti-viral that strongly inhibits CYP3A, they boosted the bioavailability of Telaprevir more than that. But the issue then becomes one of possible toxicity.
Co
Pharmacokinetic enhancement of the hepatitis C virus protease inhibitors VX-950 and SCH 503034 by co-dosing with ritonavir.
Kempf DJ, Klein C, Chen HJ, Klein LL, Yeung C, Randolph JT, Lau YY, Chovan LE, Guan Z, Hernandez L, Turner TM, Dandliker PJ, Marsh KC.
Global Pharmaceutical Research & Development Division Abbott, Abbott Park, IL, USA.
Inhibitors of hepatitis C virus (HCV) protease have shown marked antiviral activity in short-term clinical studies in HCV-infected individuals. The interaction of the investigational HCV protease inhibitors VX-950 and SCH 503034 with ritonavir, a potent inhibitor of cytochrome P450 3A, was studied in vitro and in vivo. In rat and human liver microsomes, the metabolism of VX-950 and SCH 503034 was strongly inhibited by the presence of 4 microM ritonavir. Upon co-dosing either VX-950 or SCH 503034 with ritonavir in rats, plasma exposure of the HCV protease inhibitors was increased by > 15-fold, and plasma concentrations 8 h after dosing were increased by > 50-fold. A human pharmacokinetic model of VX-950 co-administered with low-dose ritonavir suggested that improved efficacy and/or dosing convenience may be feasible by pharmacokinetic enhancement with ritonavir.
In many cases it is likely that a combination of factors such as genetic make-up, exposure to a carcinogen, age, diet, the state of your immune system, etc, play a part to trigger a cell to become abnormal, and allow it to multiply 'out of control' into a cancer.
http://www.patient.co.uk/showdoc/27000577/
Some viruses are linked to certain cancers. For example, people with persistent infection with the hepatitis B virus or the hepatitis C virus have an increased risk of developing cancer of the liver. Another example is the link between the human papilloma virus (HPV virus) and cervical cancer. Most (possibly all) women who develop cervical cancer have been infected with a strain (sub-type) of the HPV virus at some point in their life. But, most viruses and viral infections are not linked to cancer.
http://www.medhelp.org/posts/show/724750
from Schering Plough
As part of its long-term commitment to hepatitis C therapy, Schering-Plough also is developing SCH 900518 ("518"), a next-generation HCV protease inhibitor. A Phase IIa study with 518, known as the NEXT-1 study, is currently ongoing. The company said that 518 has been shown to be 10 times more potent in-vitro than other protease inhibitors currently in Phase III development and has the potential for once daily dosing. 518 also has shown decreased emergence of resistance in vitro. Given its pharmacokinetic (PK) profile, the company anticipates that 518 may be active against some HCV strains that are resistant to other protease inhibitors. Phase I proof of concept studies with 518 in treatment-naive patients and those who failed prior treatment, both as monotherapy and in combination with peginterferon (without ribavirin), demonstrated enhanced antiviral activity, with up to 4 log10 and 5 log10 decreases in circulating HCV, respectively.
-----------------------------------------------------------------------------
Vertex has 2 second generation drugs in development but has refused to comment on their efficacy other than to say that they are "competitive". I'm sure that we will hear more about that fairly soon, but even a successful second generation compound will face a slow approval process. One thing that should speed approval process is that IF Vertex were to be approved....then would not that become the new SOC? IF so...... that would mean that the new "control arms" in in some studies (with TVR) might become 24 weeks instead of 48 weeks?
best,
Willy
Eric
I've never heard of a person being interferon resistant, only the virus. Where are you drawing this definition from ?
ML
I think I'll let the heavy hitters field the answer for you....at least in part. I'll have to read these also since I am trying to stay up on the issue. Thought I'd get them out here though to keep things moving.
best,
Willy
http://www.medhelp.org/posts/show/345189
ML
So it would not be interferon resistance in the strict sense of the word, but does say that our own ability to deliver interferon to the virus and the ability of our immune system to react to interferon and attack the virus play a strong role in the success of our treatment; perhaps as much or more of a role than the ability of HCV to resist interferon.
No they are two amateur docs very knowledgeable I´m sure but still no docs.
We better hold on here a second are they speculating and mixing own thoughts with medical fact but not clearly telling what is what.
That could be dangerous in my opinion. I really would like to hear what Dr Dieterish dr Pearl , Shiffman , Jacobson or Bergs or any other heavy dr thinks about this kind of presentation (formulation) and which facts are correct and which are not !
We are all forum polices sometimes aint we, if I` m out in the blue here please police me right back.
ca
http://www.journals.uchicago.edu/doi/pdf/10.1086/515309
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1343582
viral load decline chart from the above
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1343582&rendertype=figure&id=F1
"When patients chronically infected with hepatitis C virus (HCV) are placed on antiviral therapy with pegylated interferon (IFN)-alpha or IFN-alpha plus ribavirin (RBV), HCV RNA generally declines in a biphasic manner. However, a triphasic decline has been reported in a subset of patients. A triphasic decline consists of a first phase (1-2 days) with rapid virus load decline, followed by a "shoulder phase" (4-28 days) in which virus load decays slowly or remains constant, and a third phase of renewed viral decay. We show that by including the proliferation of both uninfected and infected cells, a viral kinetic model can account for a triphasic HCV RNA decay. The model predicts that a triphasic decline occurs only in patients in which a majority of hepatocytes are infected before therapy. The shoulder phase does not represent the intrinsic death rate of infected cells, but rather the third phase slope is close to the intrinsic death rate of infected cells when overall drug efficacy is close to 1. CONCLUSION: Triphasic responses can be predicted from a generalization of existent viral kinetic models through the inclusion of homeostatic proliferation of hepatocytes. This generalized model can also explain the viral kinetics seen in flat partial responders. Finally, the enhanced third phase in patients treated with IFN-alpha in combination with RBV versus patients treated with IFN-alpha alone can be explained by a mutagenic effect of RBV against HCV."
http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=17596864&ordinalpos=144&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum
"Finally, the enhanced third phase in patientsKidney diet - dialysis patients treated with IFN-alpha in combination with RBV versus patientsKidney diet - dialysis patients treated with IFN-alpha alone can be explained by a mutagenic effect of RBV against HCV."
Kind of goes hand and hand with coming into the third phase of viral decline at the opitmun ribavirin dosage..I'm convinced my rbv dosage increases at week 4 and 8 were as critical to my svr as the treatment extension was..
I know of course by now that there exists no link to back your statements up, so I guess that is why you meet my inquiry with silence.
I have not of the indicators, high BP, HIV etc, yet I have 13 large white spots in my brain and neuropathy elsewhere.
Based on the latest things I've read, and what you just posted, can you explain why no mention is made of this possibility to patients?
Is there a way to test the spinal cord fluid or blood that would tell if such spots in the brain were HCV, so that a brain biopsy would not be necessary.
All my neurologist would say is...I don't know what's causing it. Yet I feel HCV patients should have the right to to tested and told if this is happening to them.
thanks for all and any input.
mb